Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
238 hedge funds and large institutions have $9.58B invested in Mirati Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 90 increasing their positions, 81 reducing their positions, and 46 closing their positions.
190% more call options, than puts
Call options by funds: $261M | Put options by funds: $90M
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
12% more capital invested
Capital invested by funds: $8.55B → $9.58B (+$1.02B)
11% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 81
3% less funds holding
Funds holding: 245 → 238 (-7)
11% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$188M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$56.4M |
| 3 |
AG
Artal Group
Luxembourg
|
+$56.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$54.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$49.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$106M |
| 2 |
Millennium Management
New York
|
-$70.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$67.5M |
| 4 |
BlackRock
New York
|
-$59.4M |
| 5 |
HF
HRT Financial
New York
|
-$19.1M |
MRTX Hedge Fund Activity: Q3 2021 in Review
238 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2021, worth a combined $9.58B — up 12% from $8.55B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of MRTX and 41 opened new positions — a net loss of 5 holders — while 81 trimmed existing stakes and 90 added.
The largest buyer was Ameriprise, adding an estimated $188M. The largest seller was Farallon Capital Management, cutting an estimated $106M.
- 238 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2021, down from 245 in Q2 2021.
- Funds reported $9.58B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2021, up 12% quarter-over-quarter.
- 41 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2021 and 46 closed out, a net change of -5 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2021 was Ameriprise, an estimated $188M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2021 was Farallon Capital Management, an estimated $106M sold.
Based on aggregated 13F filings for Q3 2021.